Tagged with “5-FU”
ArchivesKRAS Status Doesn’t Impact Treatment with 5-FU Alone
While researchers have found that colorectal cancer tumors that have mutated KRAS genes don’t respond to treatment with EFGR inhibitors Erbitux®(cetuximab) and Vectibix™(panitumumab), is the same thing true for other drugs?
5-FU (fluorouracil) is the backbone of most colorectal cancer treatment, given alone or in combination with other drugs. What does KRAS status mean when 5-FU is the only treatment? Continue reading…
Posted by Kate Murphy on August 2nd, 2008
Posted in: Research & Treatment News | No Comments »
Tags: 5-FU, KRAS, survival benefit
Switching from 5FU to Xeloda Can Cause Significant Side Effects
An immediate switch from 5-FU treatment to Xeloda® (capecitabine) for stage III colon cancer caused so much toxicity that a trial designed to test patient preferences for treatment had to be stopped.
Patients in the Patient Preference in Adjuvant Therapy (PACT) trial who switched after 6 weeks from weekly 5-FU with leucovorin to oral capecitabine experienced excessive side effects. The trial was designed to determine which approach to treatment patients liked best. Continue reading…
Posted by Kate Murphy on July 23rd, 2008
Posted in: Research & Treatment News | No Comments »
Tags: 5-FU, side effects, Xeloda
